BC
ACHL

Boxer Capital’s Achilles Therapeutics ACHL Stock Holding History

Boxer Capital’s Portfolio ACHL Stock Details ACHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,536,016
Closed -$12M – 88
2021
Q3 		$12M Hold
1,536,016
– – 0.42% 57
2021
Q2 		$15M Sell
1,536,016
-192
-0% -$2.6K 0.53% 57
2021
Q1 		$25.4M Buy
+1,536,208
New +$25.4M 0.86% 34

Other funds holding ACHL

SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Boxer Capital's ACHL Position: Q4 2021 in Review

Boxer Capital sold out of Achilles Therapeutics (ACHL) in Q4 2021, closing a stake of 1,536,016 shares — an estimated $12M sold.

Boxer Capital first reported a position in ACHL in Q1 2021 and held it in 3 quarters. The position peaked at $25.4M in Q1 2021. 30 funds tracked by Wall St. Rank hold ACHL as of Q4 2021.

  • Boxer Capital reported no remaining Achilles Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Boxer Capital sold 1,536,016 Achilles Therapeutics shares in Q4 2021, an estimated $12M.
  • Boxer Capital first reported a position in Achilles Therapeutics in Q1 2021 and held it in 3 quarters.
  • Boxer Capital's Achilles Therapeutics position peaked at $25.4M in Q1 2021.
  • 30 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q4 2021.

Based on Boxer Capital's 13F filing for Q4 2021, filed 14 Feb 2022.